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0.24, respectively). On day 2, cFTOE was also lower in infants 
exposed to nifedipine ± MgSO 4 (0.11, p = 0.028) and to 
MgSO 4 only (0.15, p = 0.047). sFTOE was higher in infants ex-
posed to labetalol ± MgSO 4 on days 1 (μ = 0.71) and 2 (μ = 
0.82) than in nonexposed infants (μ = 0.26, p = 0.04 and μ = 
0.55, p = 0.007, respectively). Maternal antihypertensive 
drugs did not affect rFTOE.  Conclusions: Low neonatal 
cFTOE found with maternal antihypertensive drug exposure 
may relate to either increased cerebral perfusion or neuro-
logic depression induced by the medication, or preferential 
brain perfusion associated with preeclampsia placental in-
sufficiency. Concomitantly high sFTOE found with labetalol 
exposure supports the latter, while renal autoregulation 
may explain rFTOE stability.  © 2016 The Author(s)
Published by S. Karger AG, Basel 
 Introduction 
 Hemodynamic instability is common in preterm in-
fants and often linked to immaturity and transitional car-
diovascular changes. Resulting changes in tissue perfu-
sion may cause ischemia of still immature organs  [1] . 
Nonvital organs, such as kidneys and intestines, are sup-
posedly the first to be compromised, while the brain is 
relatively protected by cerebral autoregulation  [1, 2] . Pos-
 Key Words 
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 Abstract 
 Background: Drugs with antihypertensive action are fre-
quently used in obstetrics for the treatment of preeclampsia 
(labetalol) and tocolysis (nifedipine) or for neuroprotection 
(MgSO 4 ), and may affect the hemodynamics of preterm born 
neonates.  Objective: The aim of this study was to assess 
whether maternal antihypertensive drugs affect multisite 
oxygenation levels of the neonate.  Methods: Eighty preterm 
neonates of  ≤ 32 weeks of gestational age were monitored 
using near-infrared spectroscopy. Mean cerebral, renal and 
splanchnic fractional tissue oxygen extractions (cFTOE, 
rFTOE and sFTOE) were calculated for the first 5 postnatal 
days. We determined the effect of various maternal antihy-
pertensive drugs on cFTOE and rFTOE using multilevel anal-
ysis, and on sFTOE using Kruskal-Wallis and Mann-Whitney 
U tests.  Results: Eleven infants were exposed to labetalol ± 
MgSO 4 , 7 to nifedipine ± MgSO 4 , 20 to MgSO 4 only, and 42 
to no maternal antihypertensive drugs. The infants exposed 
to labetalol ± MgSO 4 had a lower cFTOE on days 1 (0.14, p = 
0.031), 2 (0.13, p = 0.035) and 4 (0.18, p = 0.046) than nonex-
posed infants on the corresponding days (0.22, 0.20 and 
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sible consequences may be necrotizing enterocolitis 
(NEC) or dysregulation of the fluid-electrolyte balance
 [3, 4] . 
 Maternal drugs with antihypertensive properties given 
shortly before preterm delivery may present hazards to 
the perfusion and oxygenation of these newborns. Labet-
alol, an α/β-blocker, is commonly used to treat emergent 
cases of preeclampsia  [5] . Although the drug is consid-
ered safe and effective in reducing maternal blood pres-
sure, it crosses the placenta and has a half-life of about
24 h in the newborn  [5, 6] . Some have reported it to in-
duce significant neonatal hypotension  [7] . Nifedipine, a 
calcium channel-blocker commonly used as a tocolytic 
drug, is also known to have blood pressure-lowering ef-
fects, making it suitable for the treatment of maternal hy-
pertension  [5, 8] . Antihypertensive action is also seen for 
MgSO 4 (magnesium sulfate), a drug recently introduced 
for fetal neuroprotection during imminent preterm birth 
and able to directly block calcium channels  [5, 9] . Both 
nifedipine and MgSO 4 have been associated with changes 
in cerebral blood flow (CBF)  [10, 11] .
 Near-infrared spectroscopy (NIRS) is a widely ap-
proved, noninvasive method used to monitor regional 
tissue oxygen saturation (rSO 2 ) of the neonate and aids in 
the early detection of ischemic hypoxia  [4, 12] . Simulta-
neous measurements of peripheral oxygen saturation 
(SpO 2 ) can be used to derive fractional tissue oxygen ex-
traction (FTOE), reflecting not only changes in regional 
oxygen supply but also oxygen consumption  [12] . As the 
global oxygenation status of the preterm neonate is vul-
nerable and may profoundly be affected by changes in 
perfusion  [13] , our aim was to investigate the influence of 
maternal antihypertensive drugs on cerebral (c), renal (r) 
and splanchnic (s)FTOE of preterm neonates using mul-
tisite NIRS.
 Methods 
 Study Design and Population 
 We analyzed the influence of maternal antihypertensive drugs 
on neonatal NIRS data, which were previously collected at the neo-
natal intensive care unit of the University Medical Center of Gro-
ningen (UMCG) in the context of a prospective observational co-
hort study aiming to find predictors of NEC in high-risk infants. 
It is registered in the Dutch Trial Registry (CALIFORNIA trial, 
NTR3239) and has been approved by the ethical review committee 
of the UMCG. Informed parental consent was obtained for each 
infant. 
 The inclusion criteria of the CALIFORNIA trial were preterm 
birth with a gestational age (GA)  ≤ 30 weeks, a birth weight (BW) 
 ≤ 1,000 g, or being born at a GA  ≤ 32 weeks with a BW  ≤ 1,200 g, 
antenatal indomethacin exposure or congenital heart disease in-
terfering with intestinal perfusion. Exclusion criteria were chro-
mosomal disorders and abdominal diseases other than NEC. For 
the purpose of the current sub-study, newborns with congenital 
heart defects were excluded. 
 Maternal Antihypertensive Drugs 
 Based on the antihypertensive drugs most commonly adminis-
tered to the mothers of our study population, subjects were catego-
rized into four groups: exposure to labetalol ± MgSO 4 , exposure to 
nifedipine ± MgSO 4 , exposure to MgSO 4 only, and no exposure to 
maternal antihypertensive drugs. Infants with no exposure were 
identified if the maternal medical chart had no record of the use of 
any of the drugs mentioned above, including methyldopa and di-
hydralazine. Labetalol treatment of emergent hypertension was ad-
ministered intravenously, usually followed by cesarean delivery of 
the child shortly after. Nifedipine was used for tocolysis in preterm 
labor and MgSO 4 was given for either maternal or fetal neuropro-
tection, usually in combination with labetalol, nifedipine or anoth-
er tocolytic. Antihypertensive treatment with methyldopa was in-
frequent, and will thus receive no further attention in our study.
 Near-Infrared Spectroscopy 
 NIRS was performed using the INVOS 5100 near-infrared 
spectrometer (Somanetics Corp., Troy, Mich., USA) combined 
with the neonatal SomaSensor (Somanetics Corp.) to determine 
regional cerebral, renal and splanchnic oxygen saturation. Cere-
bral sensors were placed on the lateral forehead, renal sensors on 
the left or right flank just below the last costal arch, and splanchnic 
sensors below the umbilicus. Since a low BW often did not allow 
for abdominal sensor placement due to a lack of infraumbilical 
space, splanchnic measurements were less frequently performed. 
Otherwise, measurements took place every 5 s for a minimal
period of 2 stable hours within the first day after birth if possible, 
followed by measurements on the subsequent days 2, 3, 4 and 5. 
SpO 2 measured simultaneously with pulse oximetry (Nellcor) en-
abled us to compute regional FTOE using the equation FTOE = 
(SpO 2 – rSO 2 )/SpO 2  [4, 12] . FTOE can be used to assess organ per-
fusion  [12] .
 Statistical Analysis 
 The mean cFTOE, rFTOE and sFTOE values were calculated 
per day for each newborn. The statistical program MLwiN version 
2.15 (Centre for Multilevel Modelling, University of Bristol, Bris-
tol, UK) was used to determine the association between maternal 
antihypertensive drugs and both neonatal cFTOE and rFTOE us-
ing multilevel analysis. Multilevel analysis is more flexible than the 
standard repeated measures (M)ANOVA approach because it al-
lows unequal numbers of observations per individual. Separate 
models were built for cFTOE and rFTOE with the infant as level 1 
nested within the four groups of treatment at level 2. The intercept, 
also called the reference set, was day 1 in infants unexposed to ma-
ternal antihypertensive drugs and served as the baseline. As is stan-
dard for multilevel analysis  [14] , a Student t test was used to test 
for differences between the estimated mean on day 1 and the in-
tercept, and to test for differences between estimated means on 
days 2–5 a χ 2 test with one degree of freedom was used. Potential 
confounders, such as GA, BW, head circumference (HC), hemo-
dynamically significant patent ductus arteriosus (PDA), hemoglo-
bin and arterial pCO 2 , were included into the model if they had a 
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 The statistical program SPSS version 22.0 (IBM Corp., Ar-
monk, New York, N.Y., USA) was used for descriptive analyses 
and the exploration of the relationship between antihyperten-
sive drugs and sFTOE. The Kruskal-Wallis and Mann-Whitney 
U test were used without the possibility to correct for confound-
ers, as sFTOE measurements were less frequent and not nor-
mally distributed.
 To test for differences in neonatal characteristics between the 
exposure groups, the Mann-Whitney U test and the χ 2 test were 
used. For all calculations a p value  ≤ 0.05 was considered signifi-
cant. 
 Results 
 Characteristics of the Study Population 
 Of 80 preterm infants included in this study, 11 were 
exposed to labetalol ± MgSO 4 (2 of which were exposed 
to labetalol alone), 7 to nifedipine ± MgSO 4 (2 of which 
were exposed to nifedipine alone) and 20 to MgSO 4 only. 
 Table 1 presents the neonatal and maternal characteris-
tics per exposure group and indicates significant differ-













Male/female, n 28/14 2/9* 4/3 9/11
Gestational age, weeks 28.2 [26.7; 29.3] 28.1 [26.7; 28.6] 25.3** [25.0; 29.3] 28.1 [27.7; 29.5]
BW corrected for age (z score) –0.92 [–2.60; –0.14] –2.04** [–2.78; –1.40] –0.08* [–0.41; 0.72] –1.05 [–1.94; –0.14]
HC corrected for age (z score) –0.62 [–2.0; –0.07] –1.58* [–2.2; –1.01]  – 0.2 [–0.61; 0.2] –0.75 [–1.70; –0.33]
MABP (first 48 h), mm Hg 37 [32; 44] 34 [30; 45] 36 [30; 38] 38 [34; 42]
Heart rate (first 48 h), beats/min 157 [150; 163] 149* [137; 155] 154 [150; 161] 148* [139; 156]
rcSO2 (first 48 h), % 75 [69; 82] 78 [75; 87] 78 [76; 87] 79 [73; 83]
rrSO2 (first 48 h), % 67 [56; 79] 72 [51; 87] 64 [48; 80] 63 [54; 75]
rsSO2 (first 48 h), % 52 [30; 64] 17.6 [15; 25] 73 (n = 2) 48 [18; 67]
Hb levels (first 48 h), mmol/l   9.3 [8.3; 10.4] 10.3* [9.8; 11.0] 8.2** [7.4; 9.9] 9.9 [9.0; 10.6]
Arterial pCO2 levels (first 48 h), kPa 5.05 [4.61; 6.06] 6.30* [5.30; 7.05] 4.93 [3.67; 5.10] 5.50 [4.77; 5.92]
Ventilatory status (day 1)
Mechanical ventilation 21 (50.0) 6 (54.5) 2 (28.6) 10 (50.0)
CPAP/SiPAP 21 (50.0) 5 (45.5) 4 (57.1) 9 (45.0)
Oxygen flow/no assistance 0 (0.0) 0 (0.0) 1 (14.3) 1 (5.0)
hsPDA 16 (38.1) 4 (36.4) 4 (57.1) 4 (20.0)
IUGR1 7 (16.7) 5 (45.5)* 0 (0.0) 2 (10.0)
Maternal factors
Gestational hypertension2 0 (0.0) 1 (9.1) 0 (0.0) 0 (0.0)
Preeclampsia3 1 (2.4) 9 (81.8)* 0 (0.0) 1 (5.0)
HELLP syndrome4 0 (0.0) 1 (9.1) 0 (0.0) 0 (0.0)
Maternal vascular underperfusion5 11 (26.2) 8 (72.7)* 0 (0.0) 8 (33.8)
Indomethacin tocolysis 4 (9.5) 0 (0.0) 1 (14.3) 4 (20)
 Data are presented as medians and interquartile ranges [25th percentile; 75th percentile] or n (%). * Indicates a difference to new-
borns unexposed to maternal antihypertensive drugs at a significance level of p ≤ 0.05, tested using the Mann-Whitney U test or χ2 test. 
** Indicates a difference to newborns unexposed to maternal antihypertensive drugs at a significance level of p ≤ 0.1, tested using the 
Mann-Whitney U test. Hb = Hemoglobin; CPAP = continuous positive airway pressure; SiPAP = synchronized inspiratory positive air-
way pressure; hsPDA = hemodynamically significant PDA; IUGR = intrauterine growth restriction; rcSO2 = regional cerebral tissue 
oxygen saturation; rrSO2 = regional renal tissue oxygen saturation; rsSO2 = regional splanchnic tissue oxygen saturation; MABP = mean 
arterial blood pressure. 
1 Defined as an echographically estimated fetal weight below the 10th percentile. 
2 Defined as a systolic blood pressure ≥140 mm Hg and/or a diastolic blood pressure ≥90 mm Hg occurring in the second half of a 
previously normotensive pregnancy. 
3 Defined as gestational hypertension with proteinuria of ≥0.3 g protein in 24-hour urine. 
4 Defined as a combination of hemolysis, elevated liver enzymes (ASAT >70 iU/l) and low platelets (<100 × 106/l). 
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ences between infants exposed and infants unexposed to 
maternal antihypertensive drugs.
 Association between cFTOE and Exposure to 
Maternal Antihypertensive Drugs 
 Newborns exposed to maternal labetalol ± MgSO 4 
had a significantly lower cFTOE than newborns not ex-
posed to maternal antihypertensive drugs on days 1, 2 
and 4 after birth ( table  2 ;  fig.  1 ). This did not change 
when adjusting for HC, which was found to significantly 
influence cFTOE (p = 0.002). Adjusted for HC, infants 
exposed to labetalol ± MgSO 4 had a cFTOE of 0.14 (stan-
dard error, SE 0.04) on day 1, 0.13 (SE 0.05) on day 2 and 
0.18 (SE 0.05) on day 4. Compared to infants unexposed 
to maternal antihypertensive drugs, who had corre-
sponding values of 0.22 (SE 0.02), 0.20 (SE 0.02) and 0.24 
(SE 0.02), the cFTOE in infants exposed to labetalol ± 
MgSO 4 was thus 36.4% (p = 0.031) lower on day 1, 35.0% 
(p = 0.035) lower on day 2 and 25.0% (p = 0.046) lower 
on day 4. 
 Intrauterine exposure to nifedipine ± MgSO 4 and 
MgSO 4 alone resulted in a significantly lower cFTOE on 
day 2 (0.11, SE 0.06, and 0.15, SE 0.05, respectively, com-
pared to 0.2 in unexposed infants), with a corresponding 
difference of 45% (p = 0.028) and 25% (p = 0.047). 
 Association between rFTOE and Exposure to 
Maternal Antihypertensive Drugs 
 Multilevel analysis demonstrated no significant differ-
ences in renal oxygen extraction between newborns ex-
posed and newborns unexposed to maternal antihyper-
tensive drugs ( table 3 ;  fig. 2 ). Although GA and arterial 
pCO 2 had a significant influence on rFTOE (p  ≤ 0.001 
and p = 0.004, respectively), the relation between mater-
 Table 2.  Effect of maternal antihypertensive drugs on cFTOE using multilevel analysis
 Unadjusted model (n = 347) Adjusted model (n = 339)
cFTOE ( SE) difference (%) p value cFTOE (SE) difference (%) p value
Day 1
No exposure (n = 22) 0.21 (0.02) 0.22 (0.02)
Labetalol ± MgSO4 (n = 6) 0.12 (0.04) –0.09 (42.9) 0.018* 0.14 (0.04) –0.08 (36.4) 0.031*
Nifedipine ± MgSO4 (n = 5) 0.19 (0.04) –0.02 (9.5) 0.324 0.19 (0.05) –0.03 (13.6) 0.247
MgSO4 only (n = 7) 0.19 (0.04) –0.02 (9.5) 0.282 0.19 (0.04) –0.03 (13.6) 0.260
Day 2
No exposure (n = 39) 0.19 (0.02) 0.20 (0.02)
Labetalol ± MgSO4 (n = 9) 0.11 (0.05) –0.08 (42.1) 0.010* 0.13 (0.05) –0.07 (35.0) 0.035*
Nifedipine ± MgSO4 (n = 9) 0.11 (0.06) –0.08 (42.1) 0.023* 0.11 (0.06) –0.09 (45.0) 0.028*
MgSO4 only (n = 20) 0.14 (0.05) –0.05 (26.3) 0.043* 0.15 (0.05) –0.05 (25.0) 0.047*
Day 3
No exposure (n = 39) 0.19 (0.02) 0.20 (0.02)
Labetalol ± MgSO4 (n = 11) 0.16 (0.05) –0.03 (15.8) 0.367 0.18 (0.05) –0.02 (10.0) 0.613
Nifedipine ± MgSO4 (n = 7) 0.18 (0.06) –0.01 (5.3) 0.815 0.19 (0.06) –0.01 (5.0) 0.899
MgSO4 only (n = 20) 0.18 (0.05) –0.01 (5.3) 0.818 0.19 (0.05) –0.01 (5.0) 0.843
Day 4
No exposure (n = 40) 0.22 (0.02) 0.24 (0.02)
Labetalol ± MgSO4 (n = 11) 0.15 (0.05) –0.07 (31.2) 0.016* 0.18 (0.05) –0.06 (25.0) 0.046*
Nifedipine ± MgSO4 (n = 6) 0.24 (0.06) +0.02 (9.1) 0.612 0.27 (0.06) +0.03 (12.5) 0.532
MgSO4 only (n = 20) 0.19 (0.05) –0.03 (13.6) 0.319 0.21 (0.05) –0.03 (12.5) 0.304
Day 5
No exposure (n = 42) 0.23 (0.02) 0.24 (0.02)
Labetalol ± MgSO4 (n = 10) 0.20 (0.05) –0.03 (13.0) 0.299 0.21 (0.05) –0.03 (12.5) 0.505
Nifedipine ± MgSO4 (n = 7) 0.20 (0.06) –0.03 (13.0) 0.386 0.21 (0.06) –0.03 (12.5) 0.377
MgSO4 only (n = 20) 0.21 (0.05) –0.02 (8.7) 0.412 0.22 (0.05) –0.02 (8.3) 0.426
 cFTOE values are to be understood as weighted means. * Indicates a difference to newborns unexposed to maternal antihypertensive 
drugs on the corresponding day at a significance level of p ≤ 0.05. The adjusted model includes a correction for HC, which was found 
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 Fig. 1. Maternal antihypertensive drugs 
and cFTOE, presented per postnatal day 
and group of exposure in a box-and-whis-
ker plot. The boxes present interquartile 
ranges and whiskers present the total range 
of values excluding outliers; circles repre-
sent outliers. Asterisks ( * ) indicate a differ-
ence between groups at a significance level 
of p  ≤ 0.05. 
 Table 3.  Effect of maternal antihypertensive drugs on rFTOE using multilevel analysis
Unadjusted model (n = 336)  Adjusted model (n = 293)
rFTOE (SE) difference (%) p value rFTOE ( SE) difference (%) p value
Day 1
No exposure (n = 22) 0.30 (0.04) 1.24 (0.21)
Labetalol ± MgSO4 (n = 6) 0.22 (0.09) –0.08 (26.7) 0.170 1.13 (0.10) –0.11 (8.9) 0.128
Nifedipine ± MgSO4 (n = 5) 0.27 (0.10) –0.03 (10.0) 0.384 1.12 (0.09) –0.12 (9.7) 0.088**
MgSO4 only (n = 7) 0.23 (0.08) –0.07 (23.3) 0.194 1.19 (0.08) –0.05 (4.0) 0.258
Day 2
No exposure (n = 38) 0.30 (0.05) 1.23 (0.05)
Labetalol ± MgSO4 (n = 8) 0.24 (0.12) –0.06 (20.0) 0.457 1.14 (0.13) –0.09 (7.3) 0.279
Nifedipine ± MgSO4 (n = 7) 0.32 (0.13) +0.02 (6.7) 0.845 1.18 (0.11) –0.05 (4.1) 0.497
MgSO4 only (n = 19) 0.36 (0.10) +0.06 (20.0) 0.265 1.29 (0.10) +0.06 (4.9) 0.276
Day 3
No exposure (n = 38) 0.39 (0.05) 1.32 (0.05)
Labetalol ± MgSO4 (n = 11) 0.41 (0.11) +0.02 (5.1) 0.759 1.35 (0.13) +0.03 (2.3) 0.647
Nifedipine ± MgSO4 (n = 7) 0.54 (0.13) +0.15 (38.5) 0.077** 1.40 (0.11) +0.08 (6.1) 0.292
MgSO4 only (n = 20) 0.41 (0.10) +0.02 (5.1) 0.725 1.35 (0.10) +0.03 (2.3) 0.554
Day 4
No exposure (n = 36) 0.39 (0.05) 1.31 (0.05)
Labetalol ± MgSO4 (n = 11) 0.36 (0.11) –0.03 (7.7) 0.629 1.32 (0.13) +0.01 (0.8) 0.890
Nifedipine ± MgSO4 (n = 5) 0.28 (0.14) –0.11 (28.2) 0.268 1.17 (0.12) –0.14 (10.7) 0.089**
MgSO4 only  (n = 19) 0.34 (0.10) –0.05 (12.8) 0.378 1.30 (0.10) –0.01 (0.8) 0.790
Day 5
No exposure (n = 40) 0.42 (0.05) 1.34 (0.05)
Labetalol ± MgSO4 (n = 10) 0.35 (0.11) –0.07 (16.39) 0.305 1.29 (0.13) –0.05 (3.7) 0.465
Nifedipine ± MgSO4 (n = 7) 0.53 (0.13) +0.11 (26.17) 0.192 1.40 (0.11) +0.06 (4.5) 0.391
MgSO4 only (n = 20) 0.38 (0.10) –0.04 (8.25) 0.496 1.32 (0.10) –0.02 (1.5) 0.779
 rFTOE values are to be understood as weighted means. ** Indicates a difference to newborns unexposed to maternal antihyperten-
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nal antihypertensive drugs and rFTOE was not altered 
much by their inclusion into the model ( table 3 ).
 Association between sFTOE and Exposure to Maternal 
Antihypertensive Drugs 
 The differences in sFTOE between exposure groups 
reached significance on day 2 after birth (Kruskal-Wallis 
H = 9.323, p = 0.025). While differences on day 1 almost 
reached significance (Kruskal-Wallis H = 6.370, p = 
0.095), they demonstrated a p value above 0.1 on all other 
days ( fig. 3 ).
 Using the Mann-Whitney U test, we found that it was 
the group of infants exposed to labetalol ± MgSO 4 in 
whom sFTOE proved to be significantly higher on day 1 
(μ = 0.71, SD 0.05, n = 2) than in infants unexposed to 
maternal antihypertensive drugs (μ = 0.26, SD 0.14, n = 7; 
p = 0.040). This was again the case on day 2, with the 




















 Fig. 2. Maternal antihypertensive drugs 
and rFTOE, presented per postnatal day 
and group of exposure in a box-and-whis-
ker plot. The boxes present interquartile 
ranges and whiskers present the total range 
of values excluding outliers; circles repre-
sent outliers. Double asterisks ( * * ) indicate 
a difference between groups at a signifi-






















 Fig. 3. Maternal antihypertensive drugs 
and sFTOE, presented per postnatal day 
and group of exposure in a box-and-whis-
ker plot. The boxes present interquartile 
ranges and whiskers present the total range 
of values; dots represent outliers. Asterisks 
( * ) indicate a difference between groups at 
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higher than that of the controls (μ = 0.82, SD 0.02, n = 3 
and μ = 0.55, SD 0.14, n = 16, respectively; p = 0.007). The 
differences between these two groups became insignifi-
cant by day 3 (n day 3–4 = 3, and n day 5 = 1). Exposure to 
MgSO 4 only (n day 1 = 1 and n day 2–5 = 4) or nifedipine ± 
MgSO 4 (n day 1–5 = 1) did not result in significantly differ-
ent sFTOE values compared to the values of nonexposed 
newborns on any of the 5 days after birth.
 Discussion 
 We found that compared to unexposed infants, the 
cFTOE of infants exposed to maternal labetalol was sig-
nificantly lower on days 1, 2 and 4, while the sFTOE was 
higher on days 1 and 2. Additionally, a significantly low-
er cFTOE was detected in newborns exposed to maternal 
nifedipine and/or MgSO 4 on day 2 after birth. rFTOE was 
not influenced by maternal antihypertensive drugs. 
 A decreased neonatal cFTOE may be explained by an 
increase in cerebral oxygen supply or by a decrease in ce-
rebral oxygen consumption. An increase in oxygen sup-
ply may be a result of direct vasodilative drug action or 
cerebrovascular autoregulation. Kluckow and Evans  [15] 
and Evans et al.  [16] found maternal antihypertensive 
drugs to be associated with a temporary increase of post-
natal blood flow through the superior vena cava, which 
represents an indirect measure of CBF. A possible expla-
nation for this increase may be labetalol-induced vasodi-
lation impairing cerebral autoregulation, as proposed by 
Caicedo et al.  [17] . Other studies on fetal and maternal 
CBF were not able to demonstrate labetalol-induced 
changes  [18, 19] . However, a decrease in maternal cere-
bral perfusion pressure was found and suggested to result 
from an autoregulatory cerebral response to systemically 
lowered blood pressure by labetalol  [19] . 
 The high sFTOE in labetalol-exposed infants may also 
be explained by vasodilative drug action. If excessive, va-
sodilation may be strong enough to decrease the effective 
circulating volume supplying the intestines, which are 
not protected by autoregulatory mechanisms. Studies and 
case reports relating hypotension in newborns to mater-
nal labetalol support this theory  [7, 20] . Other studies 
were unable to find an association between clinically sig-
nificant hypotension and labetalol  [21] . Furthermore, we 
found mean arterial blood pressure not to be significant-
ly lower in labetalol-exposed infants ( table 1 ).
 However, especially in association with labetalol, we 
need to consider another important aspect. Oxygenation 
may also be influenced by underlying maternal disease, as 
in our study labetalol was only given in cases of maternal 
hypertension, preeclampsia or HELLP (hemolysis, ele-
vated liver enzymes, low platelets) syndrome. Preeclamp-
sia has been linked to placental abnormalities consistent 
with maternal vascular underperfusion, which was shown 
to have a tendency towards association with a lower 
cFTOE on day 2 after birth  [8, 22] . Associated chronic 
hypoxemia of the fetus commonly results in intrauterine 
growth restriction and redistribution of cardiac output to 
the brain as a compensatory, ‘brain-sparing’ mechanism 
preventing cerebral ischemia  [23] . Indeed, sub-analysis 
showed intrauterine growth restriction, defined as an 
echographically estimated fetal weight below the 10th 
percentile, and placental abnormalities consistent with 
maternal vascular underperfusion as defined by Roescher 
et al.  [22] , to be significantly more frequent in neonates 
exposed to maternal labetalol than in neonates unex-
posed to maternal antihypertensive drugs ( table 1 ). We 
were, however, unable to investigate evident fetal brain 
sparing as cerebroplacental pulsality index ratios were in-
frequently measured. Verhagen et al.  [24] , who explored 
the effect of maternal labetalol on only cFTOE with simi-
lar results, also suspected preeclampsia-associated brain 
sparing as a possible cause. Our study further supports 
this theory as we found a concomitant increase in sFTOE 
in these newborns, which may be caused by an increase 
in vascular resistance of the splanchnic circulation associ-
ated with vasoconstriction of nonvital viscera. Unfortu-
nately, we were unable to determine whether the associa-
tions found were related to labetalol or to preeclampsia of 
the mothers in this observational study. As these two fac-
tors always co-occurred in our study, future studies 
should elucidate which factor is mainly responsible for 
our cFTOE and sFTOE findings. 
 With regards to nifedipine, Harake et al.  [25] demon-
strated a 30–50% increase of fetal CBF upon low-dose 
nifedipine infusion in pregnant sheep. Others have re-
ported significantly decreased pulsatility and resistance 
indices of the fetal middle cerebral artery in the first 24–
48 h after tocolysis with nifedipine  [10, 26] . However, 
Verhagen et al.  [24] and Grzesiak et al.  [27] did not find 
an effect of nifedipine on neonatal cFTOE or fetal CBF, 
respectively. It may therefore be possible that MgSO 4 , 
which in our study was given to mothers in conjunction 
with nifedipine in 6 of the 7 subjects included, had a great-
er influence on our results. While studies on the effect of 
MgSO 4 on cerebral brain perfusion are inconsistent, a 
temporarily decreased oxygen consumption in the face of 
an unaltered CBF may be responsible for a reduction in 



















   
   
   
   
   
   
   
   
   

























 Neonatology 2016;110:163–171 
DOI: 10.1159/000445283
170
infusion of MgSO 4  [28] . Neurological depression due to 
MgSO 4 may be responsible  [5] , and this effect also needs 
to be considered when interpreting the association found 
between FTOE and labetalol, since most of the infants 
exposed to labetalol were also exposed to MgSO 4 .
 No significant association between rFTOE and mater-
nal antihypertensive drugs was found. This was surpris-
ing since we expected rFTOE to be increased due to hy-
poperfusion of the kidney associated with vasodilative 
drug action or brain-sparing perfusion. However, Petro-
va et al.  [29] , who investigated the association between 
PDA size and regional oxygenation values, demonstrated 
a similar phenomenon. While cerebral and renal oxygen-
ation was not affected by PDA size, mesenteric oxygen-
ation was reduced in the presence of a large PDA com-
bined with nasal continuous positive airway pressure. A 
possible cause for the stability of renal oxygenation may 
be intrinsic renal autoregulatory mechanisms  [2, 3] . Al-
though renal autoregulation seems to be impaired in ad-
vance of cerebral autoregulation during conditions of hy-
potension or arterial desaturation  [2, 30] , it may not be 
affected by exposure to maternal labetalol (or associated 
preeclampsia), nifedipine or MgSO 4 . Another explana-
tion for the stability of rFTOE values may be a failure to 
correctly place the NIRS sensor above the area of the kid-
ney. The values may therefore represent not only the tis-
sue oxygen extraction of the kidney, but possibly that of 
surrounding tissue other than intestinal tissue.
 The limitations of this study include the small sample 
size of newborns in whom splanchnic NIRS were per-
formed due to a lack of infraumbilical space in very low 
BW infants and the resulting inability to correct for con-
founders. The differences found, however, were large and 
significant, and should not be discarded. Further studies 
are recommended to confirm the findings or possibly de-
tect other significant differences that may have been 
missed due to the small sample sizes. Furthermore, we 
were unable to adequately study the effect of dosage and 
pharmacodynamics on FTOE values due to the retrospec-
tive nature of the collection of data concerning dosage 
and maternal size. Finally, we did not correct for maternal 
indomethacin use, which may have been of influence on 
FTOE. However, its use was infrequent and did not sig-
nificantly differ between groups.
 In summary, this was the first study to globally analyze 
the postnatal effects of maternal antihypertensive drugs 
on multisite tissue oxygen extraction in preterm neonates 
using NIRS. Using this technique at multiple sites allowed 
us to observe regional oxygenation differences within the 
exposure groups. Our results show that preterm new-
borns exposed to maternal antihypertensive drugs, par-
ticularly labetalol, have significantly lower cerebral but 
higher splanchnic oxygen extraction than unexposed 
newborns, underlining the importance of monitoring the 
cerebral and abdominal tissue oxygenation in these new-
borns during their first days of life. The exact underlying 
pathogenesis needs to be studied further, as well as the 
clinical significance of our findings on neurological out-
come and gastrointestinal function.
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